



Biogen to Participate in the 6th Annual Evercore ISI HealthCONx Conference

November 16, 2023

Cambridge, MA, -- [Biogen.com](https://www.biogen.com) announced today that Priya Signal, M.D., M.P.H., Head of Development, will participate in the 6th Annual Evercore ISI HealthCONx Conference. The webcast will be live on Tuesday, Nov 28, 2023, at 9:10 a.m. ET. To access the live webcast, please visit the Investors section of Biogen's website at investors.biogen.com. An archived version of the webcast will be available for at least 90 days following the presentation.

About Biogen

Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer's disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich's ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media - [Facebook](#), [LinkedIn](#), [X](#), [YouTube](#).

Contact:
Karen Jewell
Investor Relations
Biogen
781.464.2442